Cenegermin improves corneal healing in moderate to severe neurotrophic keratitis
Key Takeaways
- Cenegermin nearly doubled complete corneal healing at 8 weeks compared with vehicle in adults with moderate to severe neurotrophic keratitis.
- Safety was comparable between groups, with no significant difference in the rate of adverse events.
- The meta-analysis supports cenegermin as an effective disease-modifying therapy, although larger studies with longer follow-up are needed.
Topical cenegermin significantly improved corneal healing in adults with moderate to severe neurotrophic keratitis (NK) compared with vehicle, according to a study.
The analysis included 2 randomized, double-masked, vehicle-controlled trials involving 148 adults with stage 2 or 3 NK.
At 8 weeks, patients treated with cenegermin were nearly twice as likely to achieve complete corneal healing as those who received vehicle (P = 0.0001). Complete healing occurred in 72.6% of patients treated with cenegermin, compared with 38.7% in the vehicle group.
The review found no significant difference in the risk of adverse events between treatment groups (P = 0.80).
Reference
Faroog Z, Zaidi ARZ, Tejani S. Therapeutic efficacy of cenegermin in the management of neurotrophic keratitis: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Ophthalmol. 2026;18:25158414261460347. doi: 10.1177/25158414261460347. PMID: 42368179; PMCID: PMC13305801.
Related Content
